Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · February 06, 2022

Upfront Riociguat and Ambrisentan Combination Therapy for Newly Diagnosed PAH

The Journal of Heart and Lung Transplantation


Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Heart and Lung Transplantation
Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: a prospective open-label trial
J. Heart Lung Transplant 2022 Jan 10;[EPub Ahead of Print], J Weatherald, MV Thakrar, RA Varughese, et al

Further Reading